Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3647 Comments
1901 Likes
1
Kenah
Insight Reader
2 hours ago
This feels like a decision I didn’t make.
👍 147
Reply
2
Athenna
Active Reader
5 hours ago
Indices are in a consolidation phase — potential for breakout exists.
👍 47
Reply
3
Quadrell
Returning User
1 day ago
I read this and now I feel behind again.
👍 145
Reply
4
Jasonjr
Expert Member
1 day ago
Absolute wizard vibes. 🪄✨
👍 199
Reply
5
Moriel
Legendary User
2 days ago
A real treat to witness this work.
👍 227
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.